FR2845384B1 - Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique - Google Patents

Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique

Info

Publication number
FR2845384B1
FR2845384B1 FR0212369A FR0212369A FR2845384B1 FR 2845384 B1 FR2845384 B1 FR 2845384B1 FR 0212369 A FR0212369 A FR 0212369A FR 0212369 A FR0212369 A FR 0212369A FR 2845384 B1 FR2845384 B1 FR 2845384B1
Authority
FR
France
Prior art keywords
thiohydantoin
therapeutics
compounds derived
derived
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0212369A
Other languages
English (en)
Other versions
FR2845384A1 (fr
Inventor
Benaissa Boubia
Soth Samreth
Khan Ou
Evelyne Chaput
Philippe Ratel
Alan Edgar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratories Fournier SAS
Original Assignee
Laboratories Fournier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0212369A priority Critical patent/FR2845384B1/fr
Application filed by Laboratories Fournier SAS filed Critical Laboratories Fournier SAS
Priority to PCT/FR2003/002904 priority patent/WO2004031160A2/fr
Priority to AU2003279442A priority patent/AU2003279442A1/en
Priority to EP03772390A priority patent/EP1546111A2/fr
Priority to CA002500977A priority patent/CA2500977A1/fr
Priority to US10/529,817 priority patent/US20060025589A1/en
Priority to JP2004540883A priority patent/JP2006510600A/ja
Publication of FR2845384A1 publication Critical patent/FR2845384A1/fr
Application granted granted Critical
Publication of FR2845384B1 publication Critical patent/FR2845384B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0212369A 2002-10-01 2002-10-04 Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique Expired - Fee Related FR2845384B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0212369A FR2845384B1 (fr) 2002-10-04 2002-10-04 Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
AU2003279442A AU2003279442A1 (en) 2002-10-04 2003-10-03 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
EP03772390A EP1546111A2 (fr) 2002-10-04 2003-10-03 Composes derives de la 2-thiohydantoine et leur utilisation pour le traitement du diabete
CA002500977A CA2500977A1 (fr) 2002-10-04 2003-10-03 Composes derives de la 2-thiohydantoine et leur utilisation pour le traitement du diabete
PCT/FR2003/002904 WO2004031160A2 (fr) 2002-10-04 2003-10-03 Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete
US10/529,817 US20060025589A1 (en) 2002-10-01 2003-10-03 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes
JP2004540883A JP2006510600A (ja) 2002-10-04 2003-10-03 ２−チオヒダントインに由来する化合物及び治療におけるその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0212369A FR2845384B1 (fr) 2002-10-04 2002-10-04 Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique

Publications (2)

Publication Number Publication Date
FR2845384A1 FR2845384A1 (fr) 2004-04-09
FR2845384B1 true FR2845384B1 (fr) 2004-12-31

Family

ID=32011424

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0212369A Expired - Fee Related FR2845384B1 (fr) 2002-10-01 2002-10-04 Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique

Country Status (1)

Country Link
FR (1) FR2845384B1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108944B2 (en) 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
US9340524B2 (en) 2013-01-15 2016-05-17 Aragon Pharmaceuticals, Inc. Androgen receptor modulator and uses thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1709193B1 (fr) 2003-12-19 2011-03-16 The Regents of The University of California Procedes et materiaux pour evaluer des therapies du cancer de la prostate
WO2005099693A2 (fr) 2004-02-24 2005-10-27 The Regents Of The University Of California Methodes et substances permettant d'evaluer des therapies du cancer de la prostate, et composes s'y rapportant
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
AU2016201061B2 (en) * 2006-03-27 2017-03-02 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
ES2689292T3 (es) 2006-03-27 2018-11-13 The Regents Of The University Of California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
NZ572374A (en) 2006-03-29 2011-12-22 Univ California Diarylthiohydantoin compounds
EP2220050A2 (fr) 2007-10-26 2010-08-25 The Regents Of The University Of California Composés de diarylhydantoïne
CN115737643A (zh) 2012-09-26 2023-03-07 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
MX2020003845A (es) 2017-10-16 2020-11-06 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5492962A (en) * 1977-12-01 1979-07-23 Wellcome Found Thiohydantoin compound
US4743611A (en) * 1986-07-02 1988-05-10 American Home Products Corp. Naphthalenylsulfonylimidazolidinediones and their thioxo analogs useful as aldose reductase inhibitors
WO1996004248A1 (fr) * 1994-07-29 1996-02-15 Suntory Limited Derives d'imidazolidine et son utilisation
CA2238762A1 (fr) * 1995-11-28 1997-06-05 Sie-Yearl Chai Derives 2-thioxo-imidazolin-4-one et leur utilisation pour augmenter la cholesterolemie a lipoproteine de haute densite
BR0013671A (pt) * 1999-08-31 2003-06-10 Maxia Pharmaceuticals Inc Derivados heterocìclicos para o tratamento do diabetes e outras doenças

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108944B2 (en) 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
US9481664B2 (en) 2010-02-16 2016-11-01 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
US9340524B2 (en) 2013-01-15 2016-05-17 Aragon Pharmaceuticals, Inc. Androgen receptor modulator and uses thereof

Also Published As

Publication number Publication date
FR2845384A1 (fr) 2004-04-09

Similar Documents

Publication Publication Date Title
FR2823209B1 (fr) Nouvelles thiohydantoines et leur utilisation en therapeutique
MA28758B1 (fr) Composes d'aminoalkylglucosaminide phosphate et leur utilisation
IL164400A0 (en) Deruvatuves if n-Äphenyl(piperidin-2-yl)methylÜbenzamide, the preparation method thereof and application of same in therapeutics
EP1668008A4 (fr) Composes diuretiques nitroses et nitrosyles, compositions et procedes d'utilisation correspondants
FR2848115B1 (fr) Composition de bacteries et son utilisation
EP1624935A4 (fr) Composites anti-adherence et methodes d'utilisation desdits composites
IL171501A (en) Genetically engineered cutaneous microorganisms and their use
EP1608318A4 (fr) Antagonistes cxcr4 et leurs procedes d'utilisation
DE60118618D1 (de) Gelartiger polymerelektrolyt und zugehörige verwendung
PT1419150E (pt) Derivados de 1-fenilsulfonil-1,3-di-hidro-2h-indol-2-ona, sua preparacao e sua aplicacao em terapeutica
GB0401363D0 (en) Hinge unit and hinge structure using the same
EP1683788A4 (fr) Derives de pyridone, et utilisation correspondante
SI3025726T1 (sl) Spojine polimera polialkilena in njihova uporaba
EP1514679A4 (fr) Mat riau de film mince et proc d de pr paration associ
PT1513836E (pt) Derivados de piperazinilacilpiperidina, sua preparacao e sua aplicacao em terapeutica
FR2849381B1 (fr) Composition cosmetique, solaire et bio-bronzante
GB2395952B (en) Block copolymer and use thereof
EP1633749A4 (fr) Composes de deazaflavine et leurs methodes d'utilisation
IL174547A0 (en) Peptides having, for example, an antiangiogenic activity and applications thereof in therapeutics
DE60319724D1 (de) Ulticast-fähigkeit in einem atm-netzwerk
EP1696644A4 (fr) Système et procédé de test à simulation d'appel d'utilisateur à central spc numérique intégré
FR2845385B1 (fr) Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR2845635B1 (fr) Instrument composite de maintien, notamment d'ecriture et d'effacement
EP1545287A4 (fr) Composes vasoregulateurs et procedes concernant leur utilisation
FR2845383B1 (fr) Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20070629